• In early April 2026, Immunovant reported topline data showing that its two Phase 3 GO studies of batoclimab in adults with active, moderate-to-severe thyroid eye disease did not meet the primary endpoint of a 2mm or greater proptosis responder rate at Week 24, although safety remained consistent with prior findings and no new signals emerged.
• The company highlighted that proptosis improvements were greater during the initial high-dose period, reinforcing the role of deeper IgG suppression, and reaffirmed its emphasis on advancing IMVT-1402, particularly in Graves’ disease, while it reviews batoclimab’s future with partner HanAll Biopharma.
• Next, we’ll examine how batoclimab’s Phase 3 setback, despite stable safety, could affect Immunovant’s earlier investment narrative around IMVT-1402.

We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Immunovant Investment Narrative Recap

To own Immunovant, you have to believe its FcRn platform, and especially IMVT-1402, can translate clean biology into real-world autoimmune therapies despite zero current revenue and ongoing losses. The failed Phase 3 TED trials for batoclimab undercut one potential asset but do not directly change the next major catalyst, which remains IMVT-1402 data in Graves’ disease, while reinforcing the key risk that any development setback in 1402 could hit the core thesis.

The April 2026 batoclimab update sits alongside Immunovant’s earlier move to wind down most batoclimab work and expand IMVT-1402 into Sjögren's and cutaneous lupus, leaning harder into a single FcRn franchise. That shift increases the importance of 1402’s upcoming readouts as the main value driver, while past follow-on equity raises and net losses of US$357.75 million over nine months highlight how dependent the story is on successful late-stage data.

Yet beneath the focus on 1402’s upside, investors should also be aware of the risk that ongoing dilution and high implied valuation multiples could...

Immunovant's narrative projects $381.4 million in revenue and $47.7 million in earnings by 2029. This implies an earnings increase of about $512 million from -$464.2 million today.

Uncover how Immunovant's forecasts yield a $41.12 fair value, a 68% upside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were assuming about US$520.0 million of revenue and US$56.6 million of earnings by 2029, which is much rosier than consensus, so you should expect those views on trial risk and timing to evolve as the batoclimab TED miss is digested.

Explore 2 other fair value estimates on Immunovant - why the stock might be worth just $40.59!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Immunovant research is our analysis highlighting 3 important warning signs that could impact your investment decision.
• Our free Immunovant research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Immunovant's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.